admin

admin

ARO-MAPT Shows Deep CSF Tau Knockdown

Arrowhead reported interim Phase 1/2a data showing dose-dependent and durable cerebrospinal-fluid total-tau reductions after subcutaneous ARO-MAPT in healthy volunteers. Mean reduction at day 105 reached 73% at 12.8 mg/kg, with a maximum individual reduction…

FDA Accepts Tab cel BLA Resubmission

FDA accepted Pierre Fabre’s Class 2 resubmission of the tabelecleucel biologics license application for EBV-positive post-transplant lymphoproliferative disease and assigned a 31 March 2027 PDUFA date. This is a meaningful update to Insilens coverage…

Orum Doses First Patient with ORM-1153

Orum Therapeutics dosed the first patient in a Phase 1 trial of ORM-1153, a CD123-targeted degrader-antibody conjugate carrying a GSPT1 molecular-glue degrader payload, in relapsed or refractory AML and other CD123-positive hematologic malignancies. The…

SRP-1003 Shows Nuclear DMPK RNA Knockdown

Sarepta presented new preclinical data showing that its alpha-v-beta-6 integrin-targeted siRNA SRP-1003 reduced pathogenic DMPK RNA in both nuclear and cytoplasmic compartments of DM1 patient-derived myotubes, reaching approximately 80% knockdown in each. Independent assays…